We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis (INTOReTAK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04564001
Recruitment Status : Not yet recruiting
First Posted : September 25, 2020
Last Update Posted : September 25, 2020
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Takayasu arteritis (TA) is a vasculitis of unknown origin, resulting in progressive thickening and stenosis of large and medium arteries (the aorta and its major branches, and the pulmonary arteries). First line therapy of TA consists of high dose corticosteroids (CS). Between 20 and 50% of cases respond to CS alone, with subsequent resolution of symptoms and stabilization of vascular abnormalities. Although second-line agents (methotrexate, azathioprine, mercaptopurine, mycophenolate mofetil) may result in initial remission, relapses remain common when prednisone is tapered. Thus, 50% of CS-resistant or relapsing TA patients may achieve sustained remission with the addition of methotrexate. During the last decade, biologics such as anti-tumor necrosis factor alpha (anti-TNFα) and anti-interleukin-6 (anti-IL-6) have been used as third-line treatment in refractory or relapsing TA. Almost 90% of CS-methotrexate resistant TA cases responded to infliximab, an anti-TNFα, and sustained remission was obtained in 37 to 76% of the cases. Tocilizumab, an anti-IL-6 has given similar results with 68% of sustained remission in refractory TA. Irrespective of classical cardiovascular risk factors, the systemic inflammation and CS use play a pivotal role in the occurrence of cardiovascular thrombotic events (CVEs). As CVEs overlap with TA complications it is primordial to drastically taper CS in that vasculitis. We therefore hypothesize that Infliximab or Tocilizumab can achieve a remission in more than 70% of refractory/relapsing TA cases to CS associated to a second-line agent. INTOReTAK, first randomized prospective study in TA, has an original design testing Infliximab and Tocilizumab propensity to achieve over 70% of sustained remission in refractory/relapsing TA and evaluating jointly the 2 arms. The primary objective of this study is to obtain, by arm, ≥ 70% of patients at 6 months after randomization with prednisone ≤ 0.1mg/kg per day and inactive disease (NIH score ≤ 1) during the last 3 months.

Condition or disease Intervention/treatment Phase
Takayasu Arteritis Drug: Infliximab Drug: Tocilizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis
Estimated Study Start Date : September 2020
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Steroids

Arm Intervention/treatment
Experimental: A ( Infliximab)
Infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 following prescription recommendations
Drug: Infliximab
Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A

Experimental: B (Tocilizumab)
Tocilizumab : 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 following prescription recommendations
Drug: Tocilizumab
Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B

Primary Outcome Measures :
  1. Proportion of patients with prednisone ≤ 0.1mg/kg per day and sustained inactive disease (NIH score ≤ 1) from M3 to M6 and same biological therapy from randomization [ Time Frame: at 6 months after randomization ]

Secondary Outcome Measures :
  1. Incidence of relapse as defined by the NIH criteria [ Time Frame: between 3 and 6 months ]
  2. Incidence of traitement failure [ Time Frame: at 3 months after randomization ]
    Traitment failure will be defined as disease still active according to the NIH criteria

  3. Incidence of revascularization procedures [ Time Frame: at 6 months after randomization ]
  4. Incidence of revascularization procedures [ Time Frame: at 12 months after randomization ]
  5. Cumulative doses of prednisone [ Time Frame: at 6 months after randomization ]
  6. Cumulative doses of prednisone [ Time Frame: at 12 months after randomization ]
  7. Incidence of adverse events of grades III and IV [ Time Frame: at 6 months after randomization ]
  8. Incidence of adverse events of grades III and IV [ Time Frame: at 12 months after randomization ]
  9. Quality of life will be assessed using the SF36 questionnaire [ Time Frame: at 6 months ]
  10. Quality of life [ Time Frame: at 12 months ]
    Quality of life will be assessed using the SF36 questionnaire

  11. Proportion of new vascular lesions [ Time Frame: at 6 months ]
  12. Proportion of new vascular lesions [ Time Frame: at 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Takayasu disease according to the international criteria of the American College of Rheumatology (ACR)

    • Age at disease onset < 40 years
    • Claudication of extremities
    • Decreased brachial artery pulse (one or both arteries)
    • Blood pressure difference of >10mm Hg between the arms
    • Bruit over subclavian arteries or aorta
  • Active disease according to the international criteria of the National Institute of Health (NIH)
  • New onset or worsening of at least two of the following four criteria

    • Systemic features
    • Elevated erythrocyte sedimentation rate
    • Features of vascular ischemia or inflammation
    • Typical angiographic features
  • Refractory/relapsing disease

    • Failure of disease to respond to daily corticosteroids therapy (1mg/kg/day for > 1month), i.e. disease still active
    • Inability to taper corticosteroids below 10mg/day within 6 months
    • Inability to discontinue corticosteroids after 1 year of treatment
    • Relapse of disease after gradual decrease of corticosteroids therapy
  • Patients with one immunosuppressive agent (methotrexate, azathioprine, mercaptopurine or mycophenolate mofetil)
  • Age of 18 years or older
  • Weight 40 - 120 kg
  • Medical follow-up in a university or general hospital in France
  • Social insurance
  • Willing and able to provide written informed consent
  • Willing and able to comply with treatment and follow-up procedures required by the study protocol
  • For female subjects of child-bearing age, a negative serum pregnancy test and no pregnancy plans within 12 months
  • For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study. Adequate contraceptive measures include hormonal methods used for two or more cycles prior to Screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, or condom used in conjunction with contraceptive foam or jelly), intrauterine methods (IUD), sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner), and abstinence.
  • Chest X-ray results (postero-anterior and lateral) within 12 weeks prior to enrollment with no evidence of active tuberculosis, active infection, or malignancy
  • Tuberculosis assessment:

    • Active Tuberculosis infection treatment achieved
    • Completion of at least 3 weeks treatment for Latent Tuberculosis infection
    • Negative tuberculin skin test (TST) or interferon-gamma release assay (IGRA) (e.g., QuantiFERON®-TB Gold or T-spot TB® Test)

Exclusion Criteria:

  • Active tuberculosis or untreated latent tuberculosis
  • Evidence of active infection (includes chronic infection)
  • Infection requiring treatment with antibiotics within 2 weeks prior to enrollment
  • Infection with human immunodeficiency virus (HIV), hepatitis C, or a positive hepatitis B surface antigen.
  • Pregnancy or lactation
  • Inability to comply with study guidelines
  • Inability to provide informed consent
  • Immunosuppressant type or dose modification within 30 days prior to enrollment
  • Alcohol or drug abuse, that, in the investigator's opinion, could prevent a subject from fulfilling the study requirements or that would increase the risk of study procedures
  • Severe renal insufficiency (creatinine clairance <30mL/min/1,73m2)
  • Hepatic dysfunction as shown by aspartate transaminase (AST) or alanine transaminase (ALT) levels >5-fold the upper limit of normal
  • Heart failure ≥ stage III / IV NYHA,
  • History of any malignant neoplasm except adequately treated basal or squamous cell carcinoma of the skin, or solid tumors treated with curative therapy and disease free for at least 5 years.
  • History of multiple sclerosis and/or demyelinating disorder
  • History of severe allergic or anaphylactic reactions to infliximab, any chimeric murine monoclonal antibody, tocilizumab, and their respective excipients or prednisone
  • History of immediate hypersensitivity reaction to iodinated and gadolinium-based contrast media
  • Cytopenia: Hemoglobin < 8.5 g/dL, absolute neutrophil < 1.5 G/L, Platelet count < 80 G/L
  • Any live (attenuated) vaccine fewer than 4 weeks before enrolment. Recombinant or killed virus vaccines fewer than 2 weeks before enrolment.
  • Use of the following systemic treatments during the specified periods

    1. Treatment with biologic therapy (infliximab, adalimumab, certolizumab pegol, golimumab, anakinra, tocilizumab, etanercept, abatacept, ixekizumab, secukinumab, ustekinumab, alemtuzumab) within 6 months prior to enrollment
    2. Past treatment with rituximab within the past 12 months, or past treatment with rituximab more than 12 months ago where the B lymphocytes count has not returned to normal at time of enrollment
    3. Treatment with any systemic alkylating agents within 6 months prior to enrollment (e.g., cyclophosphamide, chlorambucil)
  • Lack of affiliation to a social security benefit plan (as a beneficiary or assignee)
  • Presence of any of the following disease processes:

    • Microscopic polyangiitis
    • Granulomatosis with polyangiitis
    • Eosinophilic granulomatosis with polyangiitis
    • Polyarteritis nodosa
    • Cogan's syndrome
    • Behcet's disease
    • Sarcoidosis
    • Kawasaki's disease
    • Atypical mycobacterial infections
    • Deep fungal infections
    • Lymphoma, lymphomatoid granulomatosis, or other type of malignancy tha mimics vasculitis
    • Cryoglobulinemic vasculitis
    • Systemic lupus erythematosus
    • Rheumatoid arthritis
    • Mixed connective tissue disease or any overlap autoimmune syndrome
    • Known constitutive immunodeficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04564001

Layout table for location contacts
Contact: Tristan MIRAULT +33156093051 tristan.mirault@aphp.fr
Contact: Matthieu Resche-Rigon +33142499742 matthieu.resche-rigon@univ-paris-diderot.fr

Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04564001    
Other Study ID Numbers: P160909
First Posted: September 25, 2020    Key Record Dates
Last Update Posted: September 25, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Takayasu Arteritis
Aortic Arch Syndromes
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases
Skin Diseases, Vascular
Skin Diseases
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents